Cscape Consulting Ltd 11900323 Research & Development of Medical Devices false 1 May 2024 11900323 2024-05-01 2025-04-30 11900323 2024-04-30 11900323 2025-04-30 11900323 2023-05-01 2024-04-30 11900323 2023-04-30 11900323 2024-04-30 11900323 frs102-bus:FRS102 2024-05-01 2025-04-30 11900323 frs102-bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 11900323 frs102-bus:FullAccounts 2024-05-01 2025-04-30 11900323 frs102-bus:AuditExempt-NoAccountantsReport 2024-05-01 2025-04-30 11900323 frs102-core:CurrentFinancialInstruments 2025-04-30 11900323 frs102-core:CurrentFinancialInstruments 2024-04-30 11900323 frs102-core:ShareCapital 2025-04-30 11900323 frs102-core:ShareCapital 2024-04-30 11900323 frs102-core:RetainedEarningsAccumulatedLosses 2025-04-30 11900323 frs102-core:RetainedEarningsAccumulatedLosses 2024-04-30 11900323 frs102-bus:Director1 2024-05-01 2025-04-30 xbrli:pure iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares

| Registered number
| 11900323

| Cscape Consulting Ltd |
| Unaudited Accounts |
| for the year ended |
| 30 April 2025 |

Cscape Consulting Ltd Balance Sheet as at 30 April 2025
| Notes |  | 2025 £ |  | 2024 £
--- | --- | --- | --- | --- | ---
Fixed assets |  |  |  |  |
Tangible assets |  |  | 39,011 |  | 25,735
|  |  | 39,011 |  | 25,735
Current assets |  |  |  |  |
Debtors |  | 290,248 |  | 2,100 |
Cash at bank and in hand |  | 13,885 |  | 31,111 |
|  | 304,133 |  | 33,211 |
Prepayments and accrued income: |  | 4,236 |  | 0 |
Creditors: amounts falling due within one year |  | (317,630) |  | (38,069) |
Net current assets / (liabilities) |  |  | (9,261) |  | (4,858)
Total assets less current liabilities |  |  | 29,750 |  | 20,877
Provisions for liabilities |  |  | (447) |  | (447)
Total net assets (liabilities) |  |  | 29,303 |  | 20,430
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 100 |  | 100
Profit and loss account |  |  | 29,203 |  | 20,330
Shareholders' funds |  |  | 29,303 |  | 20,430

Cscape Consulting Ltd
Balance Sheet
as at 30 April 2025

These accounts have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The directors have not delivered a copy of the company's Profit and Loss account as permitted by s444(5A) of the Companies Act 2006.

For the year ending 30 April 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Signed on behalf of the board of directors

...............................

Mr W Bennett

Director

Approved by the board on 4 April 2026

Company Number: 11900323 (a Private Company Limited by Shares registered in England and Wales)

Registered Office:

Growth Unit 8
Pembrokeshire Science And Technology Park
Pembroke Dock
SA72 6UN
Wales

Cscape Consulting Ltd
Notes to the Accounts
for the year ended 30 April 2025

1. | Accounting policies
--- | ---
| Basis of preparation of financial statements These financial statements have been prepared under the historic cost convention in accordance with the accounting policies set out below and with section 1A of FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland, and the Companies Act 2006. The presentation currency is sterling.

| Going concern basis
--- | ---
| The accounts have been prepared on the assumption that the company is able to carry on business as a going concern for the foreseeable future.

2. | Employees
--- | ---
|  | 2025 |  | 2024
| Average number of employees during the period | 1 |  | 0